The Post-COVID Mantra For Medtechs: Prioritize, Optimize And Modernize
Industry Leaders Back At The Wheel Are Driving Health Care Transformation
Medtech’s resilience and flexibility have been clear to see during the COVID-19 pandemic. In this forward-looking view for 2022, CEOs from some of the Top 50 global medtechs share their perspectives on the present and the future, from company and health care system standpoints.
You may also be interested in...
Medtronic Looks Beyond The World Of Doctors And Devices In New Approach To Markets
Focus On Switzerland – Part 2. Health warning to global medtechs: the world’s largest medtech company is taking steps to strengthen key account management, retain its market share hold and set up new health care partnerships.
The E in ESG: Philips Drives For Science-Based Targets In Carbon Zero Challenge
With a product mix that includes high energy consumption imaging, capital equipment and personal health care, Philips has a unique spectrum of challenges in driving low carbon health care. Nevertheless, it has set the bar high in environmental sustainability goals, and is pressing suppliers to follow its lead.
Switzerland: US FDA’s Medtech Can Bridge Innovation Gap Left By MDR
Setting the patient safety bar too high will likely have the opposite effect in the case of the EU MDR. So believes the medtech industry in Switzerland, where work has begun at government level to pave the way for Swiss patients to have access to US FDA-approved medtech.